Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mogamulizumab vs Vorinostat in Relapsed/Refractory CTCL
NCT01728805Phase 3Completed
- Sponsor
- Kyowa Kirin
- Start
- Nov 2012
- Primary completion
- Mar 2017
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 11
01
Overview
A Phase 3 trial of mogamulizumab in cutaneous T-cell lymphoma (CTCL), sponsored by Kyowa Kirin. Started Nov 2012; status: completed.
02
Drugs
mogamulizumab
03
Conditions
cutaneous T-cell lymphoma (CTCL)
Beyond the preview
Go deeper on NCT01728805.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01728805.